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ABSTRACT
Introduction: Voltage-gated sodium channel (VGSC)-
inhibiting drugs are commonly used to treat epilepsy
and cardiac arrhythmia. VGSCs are also widely
expressed in various cancers, including those of the
breast, bowel and prostate. A number of VGSC-
inhibiting drugs have been shown to inhibit cancer cell
proliferation, invasion, tumour growth and metastasis
in preclinical models, suggesting that VGSCs may be
novel molecular targets for cancer treatment.
Surprisingly, we previously found that prior exposure
to VGSC-inhibiting drugs may be associated with
reduced overall survival in patients with cancer, but we
were unable to control for the cause of death or
indication for prescription. The purpose of the present
study is to interrogate a different database to further
investigate the relationship between VGSC-inhibiting
drugs and cancer-specific survival.
Methods and analysis: A cohort study using
primary care data from the Clinical Practice Research
Datalink database will include patients with diagnosis
of breast, bowel and prostate cancer (13 000). The
primary outcome will be cancer-specific survival from
the date of cancer diagnosis. Cox proportional hazards
regression will be used to compare survival of patients
taking VGSC-inhibiting drugs (including antiepileptic
drugs and class I antiarrhythmic agents) with patients
with cancer not taking these drugs, adjusting for
cancer type, age and sex. Drug exposure will be treated
as a time-varying covariate to account for potential
immortal time bias. Various sensitivity and secondary
analyses will be performed.
Ethics and dissemination: The project has been
reviewed and approved by the University of York
Ethical Review Process. Results will be presented at an
international conference and published in open access
peer-reviewed journals according to the STROBE and
RECORD guidelines.
INTRODUCTION
Voltage-gated sodium channels (VGSCs) are
composed of large pore-forming α subunits
(Nav1.1–Nav1.9) and smaller auxiliary β subu-
nits (β1–β4).1 VGSCs regulate action poten-
tial ﬁring, growth and migration of
electrically excitable cells, including neurons
and myocytes.2–5 Abnormal VGSC function is
frequently a contributing factor in a number
of excitability-related disorders, including
epilepsy, cardiac arrhythmias, depression and
neuropathic pain.6 7 Thus, a number of com-
monly prescribed antiepileptic drugs and
class Ib antiarrhythmic agents, including
phenytoin, lamotrigine, carbamazepine and
valproate, elicit their therapeutic effect by
inhibiting the conductance of VGSCs.8
VGSCs are widely expressed in a number
of major cancers, including carcinomas of
the breast, prostate and colon.9–11 A number
of studies have shown that VGSC activity pro-
motes the migration and invasion of meta-
static cancer cells in vitro.12–23 Silencing
Nav1.5 expression in breast cancer cells with
shRNA inhibits tumour growth and metasta-
sis in an orthotopic xenograft breast cancer
model in mice.24 On the other hand, overex-
pression of the β1 subunit increases metasta-
sis.25 26 Furthermore, the VGSC-inhibiting
antiepileptic drug phenytoin signiﬁcantly
Strengths and limitations of this study
▪ The data source is a large prospectively collected
primary care database containing information on
causes of death, comorbidities and drug expos-
ure based on prescription data.
▪ Potential immortal time bias will be considered
and a person-time approach implemented.
▪ Cancer stage and other confounding details of
the cancer and secondary care treatments are
not available.
▪ Data on severity of epilepsy are not available.
▪ General practitioner records may be of variable
quality and invariably contain incomplete data.
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reduces migration, invasion and metastasis of cancer
cells in preclinical models, suggesting that VGSCs may
be novel molecular targets for treating metastasis.27–29
We recently conducted a systematic review of clinical
and preclinical studies testing the effects of
VGSC-inhibiting drugs in cancer.30 Only two clinical
studies were identiﬁed that explored the effect of
VGSC-inhibiting drugs in patients with cancer, and their
effect on survival and metastatic relapse was not
clear.31 32 However, we identiﬁed 22 preclinical studies
collectively, suggesting that a number of VGSC-inhibiting
drugs inhibit various aspects of cancer progression,
including proliferation, angiogenesis and invasion, sug-
gesting that further investigation in this area is urgently
required.27 28 33–52
Using data from the QResearch primary care database,
we recently considered the hypothesis that exposure to
VGSC-inhibiting drugs which started prior to cancer
diagnosis may lead to an increased time to metastasis
and thus improved survival time in patients with breast,
bowel and prostate cancer.53 We selected all patients
from the database with a diagnosis of breast, bowel or
prostate cancer and a prescription for a VGSC-inhibiting
drug prior to their cancer diagnosis. This group formed
the exposed group. The unexposed group consisted of a
random sample of patients with a breast, bowel or pros-
tate cancer diagnosis who had never had a recorded pre-
scription for a VGSC-inhibiting drug. Data on the cause
of death were not available and so our primary outcome
was all-cause mortality. In contrast to our hypothesis,
and the preclinical evidence, we found that patients with
cancer prescribed VGSC-inhibiting drugs prior to their
diagnosis had an increased all-cause mortality rate rela-
tive to the control group.54 However, we could not rule
out the possibility that the elevated mortality of the
exposed group was due to confounding by indication,
for example, epilepsy diagnosis, or differences in base-
line frailty.
The purpose of the present study is to use a different
data set from the Clinical Practice Research Datalink
(CPRD), in which we have access to data on causes of
death and life-limiting comorbidity diagnoses, in order
to test the hypothesis that exposure to VGSC-inhibiting
drugs may predict altered survival of patients with
cancer. The objectives are to investigate:
▸ the relationship between VGSC-inhibiting drug use
and cancer-speciﬁc and overall survival, controlling
for potential confounding factors, for example, epi-
lepsy and baseline frailty,
▸ the relationship between timing of VGSC-inhibiting
drug exposure (eg, before vs after cancer diagnosis)
and overall and cancer-speciﬁc survival.
METHODS AND ANALYSIS
Data source and sample selection
We will perform a retrospective cohort study using indi-
vidual patient data accessed from the CPRD database
(https://www.cprd.com/home/), a governmental,
not-for-proﬁt research service holding anonymised
primary care records drawn from participating general
(primary care) practices dating back to 1987, which can
be used for public health research. Records were
sampled in two stages. First, 125 general practices were
purposively selected to be nationally representative in
terms of area deprivation and list size. Second, up to
2500 patients were randomly sampled from each prac-
tice. The ﬁnal data set contains records for ∼289 000
patients. These data have been speciﬁcally selected to be
a large, general and nationally representative data set
for use by multiple research groups collaborating with
members of the Department of Health Sciences,
University of York, to test a range of hypotheses. We will
use these data to investigate the mortality of patients
with breast, bowel or prostate cancer stratiﬁed by
whether or not they have a recorded prescription of a
VGSC-inhibiting drug. Data relating to patient character-
istics, general practice, medical codes, clinical/consult-
ation details, referrals, immunisations, tests and
therapies (prescriptions and treatments) are available.
We will identify and extract the records for all patients
with a diagnosis of breast, bowel or prostate cancer
(hereafter referred to as the index cancers) received
before 31 December 2014 to allow at least 1 year of
follow-up for all patients. In practice we will deﬁne a
cancer diagnosis as any recording of one of these
cancers as a Medical Code (medcode, CPRD unique
code for the medical term selected by the general practi-
tioner (GP), linked to Read codes) in the clinical data
set of GP consultations in the CPRD (code list available
at clinicalcodes.org). The date of ﬁrst mention of the
cancer in the records will be used as a proxy for the
date of diagnosis, since the cancer is likely to have been
diagnosed previously in a secondary care setting. The
CPRD primary care data that we will use are not linked
to cancer registry data, such as staging and secondary
care therapy (eg, chemotherapy); therefore, these data
will not be available for this study. Patients aged younger
than 25 at the time of diagnosis will be excluded as it is
unlikely a person of that age would have one of these
three cancers. Causes of death are available and include
an underlying cause of death and, often several, con-
tributory causes.
Exposure
We will identify which patients with cancer have (ever
had) a recorded prescription for a VGSC-inhibiting drug
(table 1). For each prescription, the product name, sub-
stance, strength, formulation (tablet, gel, injection etc),
route of administration, British National Formulary
(BNF) code and header and date of administration are
recorded. The BNF header contains the licensed indica-
tion(s) for the substance, and so does not necessarily
indicate the purpose for which the prescription was
administered to the speciﬁc patient at that speciﬁc time.
The deﬁnition of exposure to VGSC-inhibiting
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medication will initially include prescriptions for lido-
caine injections, which are often used as a local anaes-
thetic. These will be excluded from the primary analyses
since we believe that these injections will have only a
transient effect and are not likely to have the same
effect as longer term prescriptions for other
VGSC-inhibiting drugs.53 However, we will compare the
outcomes of patients whose VGSC-inhibiting drug pre-
scriptions are only for lidocaine injections following
their cancer diagnosis with the unexposed group
because there is evidence that local anaesthetics used
perioperatively associate with reduced tumour
recurrence.55
The most commonly prescribed class of drug for each
patient will be identiﬁed. The extent of drug exposure
will be estimated by calculating the time between the
ﬁrst and last recorded prescription, plus a number of
weeks to account for the time they were assumed to be
taking the drug from their ﬁnal recorded prescription
(calculated as the average observed interval between pre-
scriptions for all exposed patients).
Outcome measures
Metastasis is the cause of 90% of deaths from solid
tumours;56 however, metastasis is not reliably recorded
in primary care data. Therefore, we shall investigate time
to metastasis, where possible, as a secondary outcome
but our primary outcome measure will be cancer-speciﬁc
survival (where any cancer is listed as the underlying
cause of death) following cancer diagnosis. Other sec-
ondary outcome measures will include (1) any cancer
listed among any of the causes of death; (2) index site-
speciﬁc cancer listed as the underlying cause of death; (3)
index site-speciﬁc cancer listed among any of the causes of
death and (4) all-cause mortality.
▸ A cancer death will be identiﬁed as having a derived
underlying cause code of C00-D09 in ICD-10 or
140-209 in ICD-9.
▸ A prostate cancer death will be identiﬁed as having
the derived underlying cause code of C61 in ICD-10
or 185 in ICD-9.
▸ A breast cancer death will be identiﬁed as having the
derived underlying cause of C50 in ICD-10 or 174 or
175 in ICD-9.
▸ A bowel cancer death (which includes cancers of the
colon, rectum and rectosigmoid junction) will be
identiﬁed as having a derived underlying cause of
C18-C20 in ICD-10 or 153 or 154 in ICD-9.
Confounding factors
We will consider the following confounding factors:
▸ Other life-limiting disease indications for
VGSC-inhibiting medication listed in the BNF:
epilepsy, cardiac arrhythmias, amyotrophic lateral
sclerosis and neuropathic pain/painful neuropathy.
Patients with a recorded mention of one of
Table 1 VGSC-inhibiting drugs
Drug Alternative names Target/mechanism BNF section
Amiodarone Cordarone X VGSC inhibitor 2.3.2 Antiarrhythmic drugs
Carbamazepine,
eslicarbazepine, oxcarbazepine
Arbil, Carbagen SR, Epimaz,
Inovelon, Tegretol, Teril, Timonil,
Trileptal, Zebinix
VGSC inhibitor 4.8 Antiepileptic drugs
Disopyramide Dirythmin, Isomide, Rythmodan VGSC inhibitor 2.3.2 Antiarrhythmic drugs
Dronedarone Multaq VGSC inhibitor 2.3.2 Antiarrhythmic drugs
Flecainide Tambocor VGSC inhibitor 2.3.2 Antiarrhythmic drugs
Lacosamide Vimpat VGSC inhibitor 4.8 Antiepileptic drugs
Lamotrigine Lamictal VGSC inhibitor 4.8 Antiepileptic drugs
Lidocaine Lignocaine, Xylocard VGSC inhibitor 2.3.2 Antiarrhythmic drugs
Mexiletine Mexitil VGSC inhibitor 2.3.2 Antiarrhythmic drugs
Moracizine Ethmozine VGSC inhibitor –
Phenytoin, fosphenytoin Epanutin, Pentran VGSC inhibitor 4.8 Antiepileptic drugs
Procainamide Pronestyl VGSC inhibitor –
Propafenone Arythmol VGSC inhibitor 2.3.2 Antiarrhythmic drugs
Quinidine Kiditard VGSC inhibitor –
Ranolazine Ranexa VGSC inhibitor 2.6.3 Other antianginal drugs
Riluzole Rilutek VGSC inhibitor 4.9.3 Drugs used in essential
tremor, chorea, tics, and related
disorders
Rufinamide Inovelon VGSC inhibitor 4.8 Antiepileptic drugs
Tocainide Tonocard VGSC inhibitor –
Topiramate Topamax VGSC inhibitor 4.8 Antiepileptic drugs
Valproate, valproic acid Convulex, Depakote, Epilim,
Epival, Episenta, Orlept
VGSC inhibitor 4.8 Antiepileptic drugs
Zonisamide Zonegran VGSC inhibitor 4.8 Antiepileptic drugs
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these medical codes will be identiﬁed using Read
codes;
▸ Comorbidities: the Charlson Comorbidity Index will
be calculated for each patient using Read codes for
each condition;57 58
▸ Ethnicity will be identiﬁed using Read codes, and
from linked CPRD and HES data, and will be cate-
gorised as white, mixed, Asian or Asian British, black
or black British, other and unknown;
▸ Body mass index will be identiﬁed using Read codes.
Patients will be categorised as having low (<20),
normal (20–24.9) or high (25+) BMI, or will be
placed into an ‘unknown’ category where no data are
provided. The patient’s BMI recorded at the closest
date to the date of index cancer diagnosis will be
used in the analysis;
▸ Level of physical activity will be identiﬁed using Read
codes. Patients will be categorised as undertaking
limited/light exercise, or regular exercise, according
to their status as recorded at the closest date to the
date of index cancer diagnosis;
▸ Alcohol intake will be identiﬁed using Read codes.
Patients will be categorised as non-drinker, ex-drinker,
light drinker (<3 units/day), moderate drinker (3–
6 units a day), heavy drinker (7+ units a day) or
unknown. Where alcohol use is implied but no level
of consumption is recorded, then the patient will be
assumed to be a moderate drinker. The alcohol status
recorded at the closest date to the date of index
cancer diagnosis will be used in the analysis;
▸ Smoking status will be identiﬁed using Read codes.
Patients will be categorised as non-smoker, ex-smoker,
light smoker (<9 cigarettes a day), moderate smoker
(10–19 cigarettes a day), heavy smoker (20+ cigarettes
a day) or unknown. Where it is implied that the
patient is a smoker but no level of consumption is
recorded, then the patient will be assumed to be a
moderate smoker. The smoking status recorded at the
closest date to the date of index cancer diagnosis will
be used in the analysis.
Sample size calculation
Since we shall be working with a ﬁxed data set, the size
of the sample will ultimately depend on the number of
patients in the data set with a recorded diagnosis of
breast, bowel or prostate cancer. Sample size determin-
ation for survival studies is a complex procedure. We
present here a basic calculation using parameter esti-
mates obtained from our previous study and based on
formulae presented by Shoenfeld.59 We have previously
estimated a multivariable-adjusted HR for death from
any cause among VGSC-inhibiting drug users, compared
to patients in the unexposed group, to be 1.42 (95% CI
1.36 to 1.49, p<0.001), indicating a statistically signiﬁcant
increased risk of death in the exposed group.54 To
detect this relative hazard with 80% power, given a con-
servative ratio of 20 unexposed patients per exposed
patients and a signiﬁcance level of 5%, requires 1344
events. Given a baseline event rate of 0.04 for the unex-
posed group, an average follow-up time of 5 years and a
censor rate of 0.3 requires 686 patients in the exposed
group and 13 003 patients in the unexposed group.
Shoenfeld advises that this calculation may not be reli-
able for non-randomised studies where covariates are
likely to be extremely imbalanced between the treatment
groups; however, covariates were observed to be similar
between the exposed and unexposed groups in our pre-
vious study.54
Statistical analysis
Analyses will be conducted in Stata (StataCorp LP,
College Station, Texas, USA, version 13), using two-sided
signiﬁcance tests at the 5% level. Participants with anom-
alous, incorrect or infeasible dates will be excluded, for
example, dates of cancer diagnoses recorded before
birth or after death. Cox proportional hazards regres-
sion models to analyse survival time from cancer diagno-
sis will be adjusted for drug exposure, type of cancer,
gender and age at diagnosis (age will be included as a
linear and quadratic term (age+age2)) unless otherwise
stated. Multivariable-adjusted HRs will be presented with
a 95% CI and p value.
Cox regression assumes that the proportional hazards
model applies. To assess this, we shall plot −log(−log(S
(t))) against log(time), where S(t) is the survivor func-
tion at time t. The curves for the two groups should be
parallel. We will also consider a χ2 test of the Schoenfeld
residuals to assess the null hypothesis of no relationship
between the hazards in each group. If the assumptions
are not met, we shall try to investigate why this is.
Primary data set
Participants in the CPRD data set with a recorded
medical code of one of the three index cancers diag-
nosed before 31 December 2014, and aged over 25 years
at diagnosis.
Descriptive summaries
The characteristics of the comparison groups will be
described using summary statistics. Categorical data will
be presented as frequency and percentage, and continu-
ous variables will be summarised using descriptive statis-
tics (mean, SD, median, minimum and maximum).
Comparisons between the groups will be made using χ2
tests and t-tests (or Wilcoxon rank-sum tests) as appro-
priate. A ﬂow diagram will present the selection and
exclusion (with reasons where possible) of patients in
the study. Length of exposure and the most commonly
prescribed class of drug for each patient will be sum-
marised. The underlying causes of death will be cate-
gorised as cancer, ischaemic heart disease (I20–I25 in
ICD-10 and 410 to 414 in ICD-9) and other, and sum-
marised for the two groups. The number of deaths
where epilepsy is stated as a cause will also be reported;
however, a limitation is that many deaths related to epi-
lepsy will be recorded as a different cause, such as
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accident or suicide, and it will not be possible to deﬁni-
tively attribute epilepsy to these deaths.
Replication of previous analysis
We shall replicate our initial analysis of data from the
QResearch database as closely as we can.53 54 This will
involve identifying patients in the primary data set who
were aged 30 years or older at registration. From this
cohort, patients with at least one recorded prescription
for a VGSC-inhibiting drug prior to the earliest diagnosis
of an index cancer will be identiﬁed, and prescriptions
for lidocaine removed—this group will make up the
exposed group. All patients in the primary data set, who
were aged 30 years or older at registration and who do
not have a recorded prescription, will make up the unex-
posed group. The distribution of time from cancer diag-
nosis to death (all cause) will be described using
Kaplan-Meier survival estimates for the two groups. The
statistical equivalence of the two curves will be examined
using the log-rank test. Survival from cancer diagnosis
will be compared between the exposed and unexposed
groups using an adjusted Cox proportional hazards
regression model. We will also stratify the analysis to con-
sider survival in the following two groups of patients: (1)
those whose prescriptions ended before their cancer
diagnosis and (2) those whose prescriptions continued
after their diagnosis.
Primary analysis
The primary analysis will consider cancer-speciﬁc sur-
vival using adjusted Cox proportional hazards regression
models. Right censoring will occur if the patient dies of
any other cause, is still alive at the point the data were
extracted or is transferred out of the CPRD practice. If
we simply consider drug exposure in the model as a
time-independent covariate where all person-time from
cancer diagnosis to the end of follow-up (death or
censor) is classiﬁed as ‘exposed’ for all patients with any
VGSC-inhibiting drug prescriptions (whether started
before or after diagnosis), immortal time bias60 will be
introduced for patients whose prescriptions only start
after their cancer diagnosis. To explore and account for
this issue, drug exposure status will be considered as a
time-dependent covariate in the following three ways
(ﬁgure 1):
1. patients will be considered not to be exposed until
the date they have their ﬁrst prescription (whether
before or after diagnosis) and will be assumed to be
exposed thereafter. In this scenario, all person-time
of follow-up from diagnosis to death/censor will be
classiﬁed as exposed for patients who have a prescrip-
tion before their cancer diagnosis (even those whose
last prescription precedes diagnosis); while for those
who only have prescriptions after their diagnosis,
their survival time will be classiﬁed as unexposed
between diagnosis and date of ﬁrst prescription, and
as exposed thereafter;
2. person-time will be considered as unexposed until
the date of the ﬁrst prescription and as exposed
thereafter for patients whose prescriptions either: (1)
start before diagnosis and extend after or (2) start
after diagnosis;
3. a similar but stricter approach which more closely
emulates the preclinical model27—person-time will
be considered as unexposed until the date of the ﬁrst
prescription following the date of cancer diagnosis and as
exposed thereafter.
In all scenarios, all person-time of follow-up for
patients who have never had a recorded prescription for
a VGSC-inhibiting drug will be classiﬁed as unexposed.
The distribution of time from diagnosis of cancer to
death will be described using Kaplan-Meier survival esti-
mates and Kaplan-Meier survival curves will be pre-
sented by drug exposure status. The statistical
Figure 1 Description of typical exposed and unexposed
participants in this cohort study, and the three ways we will
define drug exposure in the time-dependent analyses.
Scenario 1: person-time will be considered as unexposed until
the date of first prescription (whether before or after diagnosis)
and as exposed thereafter. Scenario 2: person-time will be
considered as unexposed until the date of first prescription
and as exposed thereafter for patients whose prescriptions
either: (1) start before diagnosis and extend after; or (2) start
after diagnosis. Scenario 3: person-time will be considered as
unexposed until the date of first prescription following the date
of cancer diagnosis and as exposed thereafter. In all
scenarios, cohort entry is date of index cancer diagnosis. All
person-time of follow-up for patients who have never had a
recorded prescription for a VGSC-inhibiting drug will be
classified as unexposed.
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equivalence of the two curves will be tested using the
log-rank test. Median time to death (or other appropri-
ate quartile), with a 95% CI, will be presented.
Sensitivity analysis
We will repeat the primary analyses adjusting the Cox
models additionally for the following confounding vari-
ables: ethnicity, BMI, physical activity, smoking status,
alcohol consumption, the Charlson Comorbidity Index
and presence of a life-limiting indication for
VGSC-inhibiting medication. In further sensitivity ana-
lyses, missing values for the confounding factors (previ-
ously included in a ‘not recorded’ category) will be
imputed using multiple imputation within Stata where
all the confounding variables and exposure to
VGSC-inhibiting drugs are included in the models.
Secondary analysis
We will consider survival stratiﬁed by cancer type using
the same model speciﬁcation as the primary analyses but
omitting cancer type as a covariate (and gender among
patients with prostate cancer).
We will repeat the primary analysis using as the
‘event’: (1) site-speciﬁc cancer listed among any of the
causes of death; (2) any cancer listed among any of the
causes of death and (3) all-cause mortality. Right censor-
ing will occur if the patient dies of any other cause
(except in case of all-cause mortality), is still alive at the
end of follow-up or is transferred out of the CPRD
practice.
Type of drug and confounding indications
We shall consider the associations for each named
VGSC-inhibiting drug by including patients in the
exposed group for the drug that they were most com-
monly prescribed (where there are sufﬁcient numbers
of patients to do so).
The prescription data for participants with a recorded
Read code for a life-limiting indication for a
VGSC-inhibiting drug will be investigated, and patients
with one of these diagnoses who do not have a recorded
prescription for a VGSC-inhibiting drug will be identi-
ﬁed and their alternative medications summarised. In
order to investigate the mortality rates of patients with
breast, bowel and prostate cancer with or without one of
these conditions and taking VGSC-inhibiting drugs or
not, the mortality of these four groups will be compared
using death from any cancer and overall survival as the
outcomes.
Lidocaine injections
We will repeat the time-dependent analyses where the
exposed group consists of patients whose
VGSC-inhibiting drug prescriptions are only for lido-
caine injections after diagnosis since there is evidence
that local anaesthetics used perioperatively associates
with reduced tumour recurrence.55
Alternative cancers
In this study, as with our previous analysis, we shall ini-
tially focus on carcinomas of the breast, bowel and pros-
tate as the role of VGSCs has been extensively studied in
these types of cancer cells, and they are among the most
common forms of cancer.9 10 However, a beneﬁt of this
unrestricted data set is that we are able to investigate our
hypotheses in patients diagnosed with other forms of
cancer in which there is also evidence that VGSCs are
expressed. We shall therefore repeat the primary analysis
including patients with a recorded mention of lung
cancer, melanoma, mesothelioma, glioma, cervical
cancer, ovarian cancer, neuroblastoma and/or
lymphoma.11
Twitter Follow Tim Doran at @narodmit and William Brackenbury at
@WJBrackenbury
Contributors WJB had the original idea for this study. CF and WJB wrote the
draft of the manuscript. IW, FM, TD and MB contributed to the development
of the idea, the study design and revised the manuscript. All authors
approved the final submitted version of the manuscript.
Funding This work was supported by Medical Research Council Fellowship
G1000508 and Wellcome Trust ref: 097829 through the Centre for Chronic
Diseases and Disorders (C2D2) at the University of York.
Competing interests None declared.
Ethics approval This project has been approved by the University of York
Ethical Review Process.
Disclaimer Patient data will not be shared outside the research team during
the project, thus maintaining confidentiality. The results of the study will be
submitted for publication in a leading open access peer-reviewed journal.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Clinical code lists will be made available at
clinicalcodes.org. The results of the study will be reported following the
Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) and REporting of studies Conducted using Observational
Routinely-collected health Data (RECORD) guidelines.61 62 The authors will
make available the full statistical analysis following publication.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Catterall WA. From ionic currents to molecular mechanisms: the
structure and function of voltage-gated sodium channels. Neuron
2000;26:13–25.
2. Brackenbury WJ, Calhoun JD, Chen C, et al. Functional reciprocity
between Na+ channel Nav1.6 and beta1 subunits in the coordinated
regulation of excitability and neurite outgrowth. Proc Natl Acad Sci
USA 2010;107:2283–8.
3. Brackenbury WJ, Yuan Y, O’Malley HA, et al. Abnormal neuronal
patterning occurs during early postnatal brain development of
Scn1b-null mice and precedes hyperexcitability. Proc Natl Acad Sci
USA 2013;110:1089–94.
4. Brackenbury WJ, Isom LL. Na channel β subunits: overachievers of
the ion channel family. Front Pharmacol 2011;2:53.
5. Patel F, Brackenbury WJ. Dual roles of voltage-gated sodium
channels in development and cancer. Int J Dev Biol
2015;59:357–66.
6. Clare JJ, Tate SN, Nobbs M, et al. Voltage-gated sodium channels
as therapeutic targets. Drug Discov Today 2000;5:506–20.
7. Brackenbury WJ, Isom LL. Voltage-gated Na+ channels: potential for
beta subunits as therapeutic targets. Expert Opin Ther Targets
2008;12:1191–203.
6 Fairhurst C, et al. BMJ Open 2016;6:e011661. doi:10.1136/bmjopen-2016-011661
Open Access
group.bmj.com on October 10, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
8. Mantegazza M, Curia G, Biagini G, et al. Voltage-gated sodium
channels as therapeutic targets in epilepsy and other neurological
disorders. Lancet Neurol. 2010;9:413–24.
9. Brackenbury WJ. Voltage-gated sodium channels and metastatic
disease. Channels (Austin) 2012;6:352–61.
10. Brackenbury WJ, Djamgoz MB, Isom LL. An emerging role for
voltage-gated Na+ channels in cellular migration: regulation of
central nervous system development and potentiation of invasive
cancers. Neuroscientist 2008;14:571–83.
11. Besson P, Driffort V, Bon É, et al. How do voltage-gated sodium
channels enhance migration and invasiveness in cancer cells?
Biochim Biophys Acta 2015;1848Pt B):2493–501.
12. Brackenbury WJ, Chioni AM, Diss JK, et al. The neonatal splice
variant of Nav1.5 potentiates in vitro invasive behaviour of
MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat
2007;101:149–60.
13. Brackenbury WJ, Djamgoz MB. Activity-dependent regulation of
voltage-gated Na+ channel expression in Mat-LyLu rat prostate
cancer cell line. J Physiol 2006;573 2):343–56.
14. Brisson L, Driffort V, Benoist L, et al. NaV1.5 Na(+) channels
allosterically regulate the NHE-1 exchanger and promote the activity
of breast cancer cell invadopodia. J Cell Sci 2013;126(Pt
21):4835–42.
15. Fraser SP, Diss JK, Chioni AM, et al. Voltage-gated sodium channel
expression and potentiation of human breast cancer metastasis.
Clin Cancer Res 2005;11:5381–9.
16. House CD, Vaske CJ, Schwartz AM, et al. Voltage-gated Na+
channel SCN5A is a key regulator of a gene transcriptional network
that controls colon cancer invasion. Cancer Res 2010;70:6957–67.
17. Grimes JA, Fraser SP, Stephens GJ, et al. Differential expression of
voltage-activated Na+ currents in two prostatic tumour cell lines:
contribution to invasiveness in vitro. FEBS Lett 1995;369:290–4.
18. Gillet L, Roger S, Besson P, et al. Voltage-gated sodium channel
activity promotes cysteine cathepsin-dependent invasiveness and
colony growth of human cancer cells. J Biol Chem
2009;284:8680–91.
19. Ding Y, Brackenbury WJ, Onganer PU, et al. Epidermal growth
factor upregulates motility of Mat-LyLu rat prostate cancer cells
partially via voltage-gated Na+ channel activity. J Cell Physiol
2008;215:77–81.
20. House CD, Wang BD, Ceniccola K, et al. Voltage-gated Na+
channel activity increases colon cancer transcriptional activity and
invasion via persistent MAPK signaling. Sci Rep 2015;5:11541.
21. Mohammed FH, Khajah MA, Yang M, et al. Blockade of
voltage-gated sodium channels inhibits invasion of
endocrine-resistant breast cancer cells. Int J Oncol 2016;48:73–83.
22. Brackenbury WJ, Djamgoz MB. Nerve growth factor enhances
voltage-gated Na+ channel activity and Transwell migration in
Mat-LyLu rat prostate cancer cell line. J Cell Physiol
2007;210:602–8.
23. Hernandez-Plata E, Ortiz CS, Marquina-Castillo B, et al.
Overexpression of NaV1.6 channels is associated with the invasion
capacity of human cervical cancer. Int J Cancer 2012;130:2013–23.
24. Nelson M, Yang M, Millican-Slater R, et al. Nav1.5 regulates breast
tumor growth and metastatic dissemination in vivo. Oncotarget
2015;6:32914–29.
25. Nelson M, Millican-Slater R, Forrest LC, et al. The sodium channel
β1 subunit mediates outgrowth of neurite-like processes on breast
cancer cells and promotes tumour growth and metastasis. Int
J Cancer 2014;135:2338–51.
26. Chioni AM, Brackenbury WJ, Calhoun JD, et al. A novel adhesion
molecule in human breast cancer cells: voltage-gated Na+ channel
beta1 subunit. Int J Biochem Cell Biol 2009;41:1216–27.
27. Nelson M, Yang M, Dowle AA, et al. The sodium channel-blocking
antiepileptic drug phenytoin inhibits breast tumour growth and
metastasis. Mol Cancer 2015;14:13.
28. Yang M, Kozminski DJ, Wold LA, et al. Therapeutic potential for
phenytoin: targeting Na(v)1.5 sodium channels to reduce migration
and invasion in metastatic breast cancer. Breast Cancer Res Treat
2012;134:603–15.
29. Fraser SP, Salvador V, Manning EA, et al. Contribution of functional
voltage-gated Na+ channel expression to cell behaviors involved in
the metastatic cascade in rat prostate cancer: I. lateral motility. J Cell
Physiol 2003;195:479–87.
30. Martin F, Ufodiama C, Watt I, et al. Therapeutic value of
voltage-gated sodium channel inhibitors in breast, colorectal and
prostate cancer: a systematic review. Front Pharmacol 2015;6:273.
31. Raderer M, Depisch D, Haider K, et al. A phase I/II study of
quinidine, a potential multidrug resistance-reversing agent, in
combination with pirarubicin in patients with advanced refractory
breast cancer. Onkologie 1993;16:450–3.
32. Wheler JJ, Janku F, Falchook GS, et al. Phase I study of anti-VEGF
monoclonal antibody bevacizumab and histone deacetylase inhibitor
valproic acid in patients with advanced cancers. Cancer Chemother
Pharmacol 2014;73:495–501.
33. Abdul M, Hoosein N. Inhibition by anticonvulsants of
prostate-specific antigen and interleukin-6 secretion by human
prostate cancer cells. Anticancer Res 2001;21:2045–8.
34. Abdul M, Hoosein N. Voltage-gated sodium ion channels in prostate
cancer: expression and activity. Anticancer Res 2002;22:1727–30.
35. Anderson JD, Hansen TP, Lenkowski PW, et al. Voltage-gated
sodium channel blockers as cytostatic inhibitors of the
androgen-independent prostate cancer cell line PC-3. Mol Cancer
Ther 2003;2:1149–54.
36. Driffort V, Gillet L, Bon E, et al. Ranolazine inhibits NaV1.5-mediated
breast cancer cell invasiveness and lung colonization. Mol Cancer
2014;13:264.
37. Al Snafi AE, Yaseen NY, Al Shatry MM. Anticancer effect of sodium
valpoate. Int J PharmTech Res 2014;7:291–7.
38. Angelucci A, Valentini A, Millimaggi D, et al. Valproic acid induces
apoptosis in prostate carcinoma cell lines by activation of multiple
death pathways. Anticancer Drugs 2006;17:1141–50.
39. Chang YC, Liu CL, Chen MJ, et al. Local anesthetics induce
apoptosis in human breast tumor cells. Anesth Analg
2014;118:116–24.
40. Fortunati N, Bertino S, Costantino L, et al. Valproic acid is a
selective antiproliferative agent in estrogen-sensitive breast cancer
cells. Cancer Lett 2008;259:156–64.
41. Iacopino F, Urbano R, Graziani G, et al. Valproic acid activity in
androgen-sensitive and -insensitive human prostate cancer cells. Int
J Oncol 2008;32:1293–303.
42. Jafary H, Ahmadian S, Soleimani M. The enhanced apoptosis and
antiproliferative response to combined treatment with valproate and
nicotinamide in MCF-7 breast cancer cells. Tumour Biol
2014;35:2701–10.
43. Jawed S, Kim B, Ottenhof T, et al. Human melatonin MT1 receptor
induction by valproic acid and its effects in combination with
melatonin on MCF-7 breast cancer cell proliferation.
Eur J Pharmacol 2007;560:17–22.
44. Jiang W, Zheng Y, Huang Z, et al. Role of SMAD4 in the
mechanism of valproic acid’s inhibitory effect on prostate cancer cell
invasiveness. Int Urol Nephrol 2014;46:941–6.
45. Li GF, Qian TL, Li GS, et al. Sodium valproate inhibits MDA-MB-231
breast cancer cell migration by upregulating NM23H1 expression.
Genet Mol Res 2012;11:77–86.
46. Li K, Yang J, Han X. Lidocaine sensitizes the cytotoxicity of cisplatin
in breast cancer cells via up-regulation of RARβ2 and RASSF1A
demethylation. Int J Mol Sci 2014;15:23519–36.
47. Olsen CM, Meussen-Elholm ET, Røste LS, et al. Antiepileptic drugs
inhibit cell growth in the human breast cancer cell line MCF7.
Mol Cell Endocrinol 2004;213:173–9.
48. Papi A, Ferreri AM, Guerra F, et al. Anti-invasive effects and
proapoptotic activity induction by the rexinoid IIF and valproic acid in
combination on colon cancer cell lines. Anticancer Res
2012;32:2855–62.
49. Wedel S, Hudak L, Seibel JM, et al. Impact of combined HDAC and
mTOR inhibition on adhesion, migration and invasion of prostate
cancer cells. Clin Exp Metastasis 2011;28:479–91.
50. Yoon JR, Whipple RA, Balzer EM, et al. Local anesthetics inhibit
kinesin motility and microtentacle protrusions in human epithelial
and breast tumor cells. Breast Cancer Res Treat 2011;129:691–701.
51. Zhang L, Wang G, Wang L, et al. Valproic acid inhibits prostate
cancer cell migration by up-regulating E-cadherin expression.
Pharmazie 2011;66:614–18.
52. Zhang L, Wang G, Wang L, et al. VPA inhibits breast cancer cell
migration by specifically targeting HDAC2 and down-regulating
Survivin. Mol Cell Biochem 2012;361:39–45.
53. Fairhurst C, Watt I, Martin F, et al. Exposure to sodium
channel-inhibiting drugs and cancer survival: protocol for a cohort
study using the QResearch primary care database. BMJ Open
2014;4:e006604.
54. Fairhurst C, Watt I, Martin F, et al. Sodium channel-inhibiting drugs
and survival of breast, colon and prostate cancer: a
population-based study. Sci Rep 2015;5:16758.
55. Biki B, Mascha E, Moriarty DC, et al. Anesthetic technique for
radical prostatectomy surgery affects cancer recurrence: a
retrospective analysis. Anesthesiology 2008;109:180–7.
56. Gupta GP, Massagué J. Cancer metastasis: building a framework.
Cell 2006;127:679–95.
57. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying
prognostic comorbidity in longitudinal studies: Development and
validation. J Chronic Dis 1987;40:373–83.
Fairhurst C, et al. BMJ Open 2016;6:e011661. doi:10.1136/bmjopen-2016-011661 7
Open Access
group.bmj.com on October 10, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
58. Li B, Evans D, Faris P, et al. Risk adjustment performance of
Charlson and Elixhauser comorbidities in ICD-9 and ICD-10
administrative databases. BMC Health Serv Res 2008;8:12.
59. Schoenfeld DA. Sample-size formula for the proportional-hazards
regression model. Biometrics 1983;39:499–503.
60. Suissa S. Immortal time bias in observational studies of drug effects.
Pharmacoepidemiol Drug Saf 2007;16:241–9.
61. von Elm E, Altman DG, Egger M, et al. Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE)
statement: guidelines for reporting observational studies. BMJ
2007;335:806–8.
62. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of
studies Conducted using Observational Routinely-collected health
Data (RECORD) statement. PLoS Med 2015;12:e1001885.
8 Fairhurst C, et al. BMJ Open 2016;6:e011661. doi:10.1136/bmjopen-2016-011661
Open Access
group.bmj.com on October 10, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
the CPRD primary care database
survival: protocol for a cohort study using 
Sodium channel-inhibiting drugs and cancer
William J Brackenbury
Caroline Fairhurst, Fabiola Martin, Ian Watt, Tim Doran, Martin Bland and
doi: 10.1136/bmjopen-2016-011661
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/9/e011661
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/6/9/e011661
This article cites 62 articles, 10 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (380)Pharmacology and therapeutics
 (339)Oncology
 (324)Neurology
 (1717)Epidemiology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on October 10, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
